Rokit Healthcare (376900.KQ) reported first-quarter revenue more than doubled from a year earlier, driven by business expansion at home and abroad.
The company posted consolidated first-quarter revenue of 8.1 billion won and an operating loss of 2.4 billion won, it said Tuesday. Revenue grew 118% from the same period last year.
The revenue growth reflects a combination of factors, including expanded business activities at home and abroad, stronger overseas market capabilities, and a more diversified revenue portfolio. The company is broadening its business foundation in key overseas markets such as the United States and the Middle East, while continuing preparations to enhance the global commercialization potential of its artificial intelligence (AI) organ regeneration platform.
The operating loss widened to 2.4 billion won from 200 million won a year earlier. The company attributed the wider loss to concentrated spending on future revenue sources, including the global clinical expansion of its AI cartilage regeneration platform, domestic research on its AI diabetic foot regeneration platform, an AI kidney predictive diagnosis platform, responses to global regulatory and licensing requirements, and upgrades to its AI-based digital healthcare platform.
"Despite the first quarter being a traditional off-season for the industry, we proved our marketability by more than doubling revenue from a year earlier," a Rokit Healthcare official said. "With market entries in the United States, Saudi Arabia, and Latin America proceeding as planned, this year will be one in which we solidify our first-mover position in the AI organ regeneration platform."
Rokit Healthcare's main business is its AI hyper-personalized organ regeneration platform, which combines medical lesion modeling AI, single-use regeneration kits, hyper-personalized bioink, and a medical 3D bioprinter.
